Arcellx (NASDAQ:ACLX) Reaches New 12-Month High - Here's What Happened

Key Points

• Arcellx shares hit a new 52-week high of $114.94 mid-day, and analysts have clustered around a ~$115 price target; the consensus rating is currently Hold with an average target of $111.87.
• The company remains unprofitable — it reported EPS of ($1.01) (in line with estimates) but revenue of $1.65M missed expectations of $13.4M, alongside a negative ROE (55.42%) and a deeply negative net margin.
• Insiders have been net sellers (109,366 shares worth about $11.5M over the past 90 days, including an $10.24M sale by Rami Elghandour), while institutional ownership is very high (~96%) and major funds like T. Rowe Price and Vestal Point materially increased stakes.

Arcellx, Inc. (NASDAQ:ACLX - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $114.94 and last traded at $114.8950, with a volume of 455581 shares. The stock had previously closed at $114.82.

Analysts Set New Price Targets

ACLX has been the topic of several analyst reports. Canaccord Genuity Group set a $115.00 target price on Arcellx in a report on Monday, February 23rd. Leerink Partners reiterated a "market perform" rating and set a $115.00 price objective on shares of Arcellx in a research note on Tuesday, February 24th. Stifel Nicolaus restated a "hold" rating and issued a $115.00 target price (down from $127.00) on shares of Arcellx in a research report on Monday, February 23rd. Robert W. Baird restated a "neutral" rating and set a $115.00 target price (up from $106.00) on shares of Arcellx in a research note on Monday, February 23rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcellx in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $111.87.

Arcellx Price Performance

The business's 50-day simple moving average is $93.18 and its two-hundred day simple moving average is $82.91. The stock has a market cap of $6.71 billion, a price-to-earnings ratio of -28.21 and a beta of 0.23.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.01) EPS for the quarter, meeting analysts' consensus estimates of ($1.01). The company had revenue of $1.65 million during the quarter, compared to analysts' expectations of $13.40 million. Arcellx had a negative return on equity of 55.42% and a negative net margin of 1,027.26%. Equities research analysts forecast that Arcellx, Inc. will post -1.58 earnings per share for the current year.

Insider Activity

In other Arcellx news, insider Rami Elghandour sold 89,916 shares of the business's stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the sale, the insider directly owned 276,051 shares of the company's stock, valued at $31,447,729.92. The trade was a 24.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Christopher Heery sold 5,882 shares of the firm's stock in a transaction on Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total transaction of $402,975.82. Following the transaction, the insider directly owned 23,749 shares of the company's stock, valued at $1,627,043.99. The trade was a 19.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 109,366 shares of company stock worth $11,526,708. Company insiders own 8.35% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. increased its stake in shares of Arcellx by 66.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,560,425 shares of the company's stock valued at $688,540,000 after buying an additional 4,208,069 shares during the period. Vestal Point Capital LP boosted its holdings in Arcellx by 134.0% in the fourth quarter. Vestal Point Capital LP now owns 2,925,000 shares of the company's stock valued at $190,710,000 after acquiring an additional 1,675,000 shares during the last quarter. Paradigm Biocapital Advisors LP increased its position in Arcellx by 23.1% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 5,724,016 shares of the company's stock valued at $373,206,000 after purchasing an additional 1,075,000 shares during the period. Decheng Capital LLC increased its position in Arcellx by 995.2% during the 2nd quarter. Decheng Capital LLC now owns 547,609 shares of the company's stock valued at $36,060,000 after purchasing an additional 497,609 shares during the period. Finally, State Street Corp raised its holdings in Arcellx by 31.0% during the 4th quarter. State Street Corp now owns 1,998,503 shares of the company's stock worth $130,302,000 after purchasing an additional 472,476 shares during the last quarter. 96.03% of the stock is owned by institutional investors.

About Arcellx

Arcellx, Inc NASDAQ: ACLX is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.